Antimicrobial resistance of H. pylori to the outcome of 10-days vs. 7-days Moxifloxacin based therapy for the eradication: a randomized controlled trial

被引:20
作者
Bago, Josip [1 ]
Majstorovic, Karolina [1 ]
Belosic-Halle, Zeljka [1 ]
Kucisec, Nastja [2 ]
Bakula, Vinko [1 ]
Tomic, Monika [3 ]
Bago, Petra [1 ]
Troskot, Rosana [1 ]
机构
[1] Clin Hosp Sveti Duh, Internal Med Clin, Dept Gastroenterol, Zagreb, Croatia
[2] Clin Hosp Sveti Duh, Dept Microbiol, Zagreb, Croatia
[3] Univ Hosp Mostar, Internal Med Clin, Dept Gastroenterol, Mostar, Bosnia & Herceg
关键词
Pylorus Infection; Levofloxacin; Moxifloxacin; Lansoprazole; Pylorus Eradication;
D O I
10.1186/1476-0711-9-13
中图分类号
Q93 [微生物学];
学科分类号
071005 [微生物学];
摘要
Introduction: Antibiotic resistance decreases success of Helicobacter pylori (Hp) eradication. Recently published results show low rate of resistance and better compliance with moxifloxacin based regiments. Aims&methods: Whether 7 days moxifloxacin with lansoprasole and amoxycillin can be compared with 10 days moxifloxacin with lansoprasole and amoxycillin according to moxifloxacin resistance. Patients with non-ulcer dyspepsia who had culture and histology positive Hp infection (n = 150) were randomly assigned into two groups. The first group (n = 75) received moxifloxacin 400 mg/d during 7 days and the other (n = 75) received moxifloxacin 400 mg/d during 10 days. All patients received amoxycillin 1 g twice daily, lansoprasole 30 mg twice daily. All Hp cultures were tested for sensitivity to moxifloxacin. Results: 138 patients (92%) completed the study, 68 in the first group and 70 in the second. Eradication rates were 84% (57/68) and 76% (57/75) in the 7 days moxifloxacin group and 90% and 84% in the second group (63/70, 63/75) according to the PP and ITT analysis; p = n.s. Among 129 patients (86% of study group), 6% of strains were primary resistant to moxifloxacin. Eradication of moxifloxacin sensitive/resistant strains was 98%/66%, p < 0.05 Conclusion: According to our results we recommend 7 days moxiflixacin based triple therapy.
引用
收藏
页数:6
相关论文
共 28 条
[1]
7-day triple therapy of Helicobacter pylori infection with levofloxacin, amoxicillin, and high-dose esomeprazole in patients with known antimicrobial sensitivity [J].
Antos, D ;
Schneider-Brachert, W ;
Bästlein, E ;
Hänel, C ;
Haferland, C ;
Buchner, M ;
Meier, E ;
Trump, F ;
Stolte, M ;
Lehn, N ;
Bayerdörffer, E .
HELICOBACTER, 2006, 11 (01) :39-45
[2]
Bago J, 2002, WIEN KLIN WOCHENSCHR, V114, P448
[3]
Hohe eradikationsrate von H-Pylori mit moxifloxacin-basierter therapie:: Eine randomisierte kontrollierte studie [J].
Bago, Petra ;
Vcev, Aleksandar ;
Tomic, Monika ;
Rozankovic, Marjan ;
Marusic, Marinko ;
Bago, Josip .
WIENER KLINISCHE WOCHENSCHRIFT, 2007, 119 (11-12) :372-378
[4]
Prevalence and mechanisms of resistance to fluoroquinolones in Helicobacter pylori strains from patients living in Belgium [J].
Bogaerts, Pierre ;
Berhin, Catherine ;
Nizet, Henri ;
Glupczynski, Youri .
HELICOBACTER, 2006, 11 (05) :441-445
[5]
Efficacy of two one-week rabeprazole/levofloxacin-based triple therapies for Helicobacter pylori infection [J].
Cammarota, G ;
Cianci, R ;
Cannizzaro, O ;
Cuoco, L ;
Pirozzi, G ;
Gasbarrini, A ;
Armuzzi, A ;
Zocco, MA ;
Santarelli, L ;
Arancio, F ;
Gasbarrini, G .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2000, 14 (10) :1339-1343
[6]
Update on fluoroquinolone resistance in Helicobacter pylori:: new mutations leading to resistance and first description of a gyrA polymorphism associated with hypersusceptibility [J].
Cattoir, Vincent ;
Nectoux, Juliette ;
Lascols, Christine ;
Deforges, Lionel ;
Delchier, Jean-Charles ;
Megraud, Francis ;
Soussy, Claude-James ;
Cambau, Emmanuelle .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2007, 29 (04) :389-396
[7]
Della Monica P, 2002, ALIMENT PHARM THER, V16, P1269
[8]
Levofloxacin based regimens for the eradication of Helicobacter pylori [J].
Di Caro, S ;
Zocco, MA ;
Cremonini, F ;
Candelli, M ;
Nista, EC ;
Bartolozzi, F ;
Armuzzi, A ;
Cammarota, G ;
Santarelli, L ;
Gasbarrini, A .
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2002, 14 (12) :1309-1312
[9]
Mono, dual and triple moxifloxacin-based therapies for Helicobacter pylori eradication [J].
Di Caro, S ;
Ojetti, V ;
Zocco, MA ;
Cremonini, F ;
Bartolozzi, F ;
Candelli, M ;
Lupascu, A ;
Nista, EC ;
Cammarota, G ;
Gasbarrini, A .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2002, 16 (03) :527-532
[10]
Impact of clarithromycin resistance on the effectiveness of a regimen for Helicobacter pylori:: a prospective study of 1-week lansoprazole, amoxycillin and clarithromycin in active peptic ulcer [J].
Ducóns, JA ;
Santolaria, S ;
Guirao, R ;
Ferrero, M ;
Montoro, M ;
Gomollón, F .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 1999, 13 (06) :775-780